Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes

瞬态弹性成像 医学 内科学 失代偿 肝活检 队列 2型糖尿病 前瞻性队列研究 肝纤维化 2型糖尿病 糖尿病 队列研究 肝病 胃肠病学 糖化血红素 脂肪肝 脂肪变性 活检 丙型肝炎 外科 肝病学 纤维化 试验预测值 回顾性队列研究 非酒精性脂肪肝 代谢综合征
作者
Yuping Chen,Bingtian Dong,Xinrui Jin,Chuan Liu,Ming-Hua Zheng,Xiao Liang,Yameng Sun,Hye Won Lee,Huapeng Lin,Emmanuel Tsochatzis,Salvatore Petta,Elisabetta Bugianesi,Masato Yoneda,Hannes Hagström,Jérôme Boursier,Calleja Jl,George Boon-Bee Goh,W. F. Chan,Rocio Gallego-Durán,Arun J Sanyal
出处
期刊:Gut [BMJ]
卷期号:75 (3): 576-587 被引量:5
标识
DOI:10.1136/gutjnl-2025-337506
摘要

BACKGROUND: Current guidelines recommend a two-step approach for risk stratification of metabolic dysfunction-associated steatotic liver disease (MASLD), starting with Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE). OBJECTIVE: To evaluate this approach for predicting advanced fibrosis and liver-related events (LREs) in patients with type 2 diabetes (T2D). DESIGN: A prospective liver biopsy cohort of T2D patients with histologically confirmed MASLD from seven centres in China was used to assess diagnostic performance for advanced fibrosis. The international VCTE-Prognosis cohort, including T2D patients with MASLD who underwent VCTE at 16 centres in the USA, Europe and Asia, with longitudinal follow-up, was used to assess LREs, defined as hepatic decompensation or hepatocellular carcinoma. RESULTS: 4781 participants were included. In the liver biopsy cohort (n=352; 22.2% with advanced fibrosis), applying LSM thresholds of <8 kPa and >12 kPa after FIB-4 classified patients into 63.4% low-risk, 9.4% intermediate-risk and 27.3% high-risk, with a correct classification rate of 71%. In the VCTE-Prognosis cohort (n=4429; median follow-up 51.3 (IQR 27.4-70.7) months), 140 (3.2%) patients developed LREs (110 (2.5%) with hepatic decompensation and 59 (1.3%) with hepatocellular carcinoma). The two-step approach classified 72.6%, 6.8% and 20.6% of patients into low-risk, intermediate-risk and high-risk groups, with corresponding 5-year cumulative LRE incidences of 0.7%, 0.9% and 11.8%. Refining classification of intermediate FIB-4 patients using LSM <10 kPa (low-risk) and >15 kPa (high-risk) reduced the intermediate-risk group to 5.6% while preserving predictive accuracy. CONCLUSION: The non-invasive two-step approach of FIB-4 followed by LSM effectively stratifies MASLD-related advanced fibrosis and LREs risk in T2D. Applying LSM cut-offs of 10 and 15 kPa further optimises risk stratification for future LREs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无花果应助zhuquan采纳,获得10
2秒前
酒醉梦成真完成签到 ,获得积分10
2秒前
一帆丿风顺完成签到,获得积分10
2秒前
2秒前
3秒前
南庭发布了新的文献求助10
4秒前
英姑应助顺利毕业采纳,获得10
4秒前
科研通AI6.4应助a海w采纳,获得10
4秒前
思源应助科研熊采纳,获得10
7秒前
肇秋1一发布了新的文献求助10
9秒前
得之我幸完成签到,获得积分10
9秒前
11秒前
dde应助科研通管家采纳,获得10
11秒前
共享精神应助科研通管家采纳,获得10
11秒前
JamesPei应助科研通管家采纳,获得30
11秒前
11秒前
我是老大应助意难天采纳,获得10
11秒前
华仔应助科研通管家采纳,获得10
11秒前
852应助科研通管家采纳,获得10
12秒前
Hello应助科研通管家采纳,获得10
12秒前
Owen应助科研通管家采纳,获得20
12秒前
丘比特应助科研通管家采纳,获得10
12秒前
小二郎应助科研通管家采纳,获得10
12秒前
12秒前
心灵尔安完成签到,获得积分10
12秒前
今后应助科研通管家采纳,获得10
12秒前
12秒前
13秒前
molihuakai应助科研通管家采纳,获得10
13秒前
晚风完成签到 ,获得积分10
13秒前
14秒前
予吾发布了新的文献求助10
14秒前
淑桐完成签到,获得积分10
15秒前
张欢馨应助自由的芷烟采纳,获得10
15秒前
Ava应助大大怪采纳,获得10
16秒前
Lucas应助哇塞的采纳,获得10
16秒前
科研通AI6.4应助鱼籽派采纳,获得10
17秒前
Og完成签到,获得积分10
17秒前
18秒前
萝卜青菜发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
An Introduction to Foreign Language Learning and Teaching 750
China Pluperfect I: Epistemology of Past and Outside in Chinese Art 520
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
Cosmos as Art Object: Studies in Plato's Timaeus and Other Dialogues 500
What is the Future of Psychotherapy in Digital Age? Technology, AI Bots, and Psychotherapy after Covid 444
煤炭地下气化渗流燃烧方法的研究 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7632253
求助须知:如何正确求助?哪些是违规求助? 9206694
关于积分的说明 19745346
捐赠科研通 7201590
什么是DOI,文献DOI怎么找? 3274772
关于科研通互助平台的介绍 2436709
邀请新用户注册赠送积分活动 2271458